Legal Representation
Attorney
J. PAUL WILLIAMSON
USPTO Deadlines
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 28, 2005 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 27, 2005 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 29, 2004 | CFIT | O | CASE FILE IN TICRS | Loading... |
| Feb 12, 2004 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 27, 2004 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 27, 2004 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 25, 2003 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jul 24, 2003 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jul 24, 2003 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 31, 2003 | I | PAPER RECEIVED | Loading... | |
| Mar 29, 2003 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Mar 14, 2003 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 24, 2002 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Dec 24, 2002 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 18, 2002 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 8, 2002 | I | PAPER RECEIVED | Loading... | |
| Aug 13, 2002 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 21, 2002 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 1, 2002 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Nov 29, 2001 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 19, 2001 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 27, 2001 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 9, 2001 | UNPR | I | UNRESPONSIVE/DUPLICATE PAPER RECEIVED | Loading... |
| Jun 27, 2001 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Jun 14, 2001 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Detailed Classifications
Class 005
PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF ARTHRITIS, PAIN, INFLAMMATION, CARDIOVASCULAR DISEASES, ONCOLOGY, OPTHALMOLOGICAL CONDITIONS, CENTRAL NERVOUS SYSTEM DISORDERS
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005